CD226 and neoplasm: The in vitro and in vivo tumor-lytic capacity was associated with the expression of natural cytotoxicity receptors (NKp30, NKp44), activation receptors (NKG2D, DNAM-1), and adhesion molecules (CD11a, ICAM-1) (92).